Related Experiment Video
Updated: May 12, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Erlotinib in the first-line treatment of non-small-cell lung cancer
Manolo D'Arcangelo1, Federico Cappuzzo
1Istituto Toscano Tumori, Ospedale Civile, Viale Alfieri 36, 57100, Livorno, Italy.
Abstract:
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most important molecular aberrations in NSCLC. Drugs interfering with the tyrosine kinase domain of the EGFR (EGFR-TKI), such as erlotinib or gefitinib, demonstrated efficacy in patients with advanced NSCLC irrespective of therapy line and particularly in patients harboring activating mutations of the EGFR gene. Results of large Phase III randomized trials clearly demonstrated that an EGFR-TKI is the best front-line option for patients with classical EGFR mutations, while in the EGFR wild-type or EGFR unknown population platinum-based chemotherapy remains the gold standard. In pretreated patients, EGFR-TKIs are considered more effective than standard chemotherapy in the EGFR-mutated population, with no difference in EGFR wild-type NSCLC. Although EGFR-TKIs are certainly particularly effective in patients with EGFR mutations, at present no biomarker, including KRAS mutations, can be recommended in clinical practice for precluding the therapy to any pretreated patient. In this article, the authors analyzed data of erlotinib in NSCLC, focusing on its role in front-line therapy.
Insights
Erlotinib, an EGFR-TKI, is a top front-line choice for non-small-cell lung cancer (NSCLC) patients with EGFR mutations. It shows efficacy in advanced NSCLC, especially with specific gene mutations.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
- The Epidermal Growth Factor Receptor (EGFR) signaling pathway is a key molecular target in NSCLC.
- EGFR-Tyrosine Kinase Inhibitors (TKIs) have shown significant efficacy in NSCLC treatment.
Purpose of the Study:
- To analyze the efficacy of erlotinib in NSCLC treatment.
- To focus on the role of erlotinib as a front-line therapy option.
- To review the impact of EGFR mutations on TKI effectiveness.
Main Methods:
- Review of data from erlotinib studies in NSCLC.
- Analysis of Phase III randomized trials.
- Comparison of EGFR-TKI efficacy versus chemotherapy based on EGFR mutation status.
Main Results:
- EGFR-TKIs, including erlotinib, are superior to chemotherapy as front-line treatment for NSCLC patients with activating EGFR mutations.
- In pretreated patients, EGFR-TKIs are more effective than chemotherapy in the EGFR-mutated population.
- For EGFR wild-type or unknown NSCLC, platinum-based chemotherapy is the standard front-line option.
Conclusions:
- EGFR-TKIs represent a crucial therapeutic strategy for NSCLC, particularly in patients with EGFR mutations.
- Erlotinib's role in front-line therapy for EGFR-mutated NSCLC is well-established.
- Current biomarkers do not preclude EGFR-TKI therapy in pretreated patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...